9 Meters Biopharma, Inc. (NASDAQ:NMTR) with the stream of 1.63% in the last hour of trading session.
9 Meters Biopharma, Inc. (NMTR) had a good day on the market for Friday January 22 as shares jumped 1.63% to close at $1.25. About 5,252,787 million shares traded hands on 7.57M trades for the day, compared with an average daily volume of 7.57M shares out of a total float of 116.68M. After opening the trading day at $1.22, shares of 9 Meters Biopharma, Inc. stayed within a range of $1.21 to $1.29.
With today’s gains, 9 Meters Biopharma, Inc. now has a market cap of $249.30M. Shares of 9 Meters Biopharma, Inc. have been trading within a range of $0.37 and $1.77 over the last year, and it had a 50-day SMA of $26.19% and a 200-day SMA of $75.79%.
The PEG ratio is used to determine a stock’s value while taking the company’s earnings growth into account, and is considered to provide a more complete picture than the P/E ratio. Last traded has a PEG ratio of 0 where as its P/E ratio was 0. The overall volume in the last trading session was 5,252,787 shares.
9 Meters Biopharma, Inc. has P/S value of 0 while its P/B esteem remains at 41.67. Likewise, the company has Return on Assets of -704.10%, Return on Equity of 0 and Return on Investment of 0. The company demonstrates Gross Margin and Operating Margin of 0 and 0 respectively.
NMTR’s price to sales ratio for trailing twelve months was 0 and price to book ratio for most recent quarter was 41.67, whereas price to cash per share for the most recent quarter was 20.10. The Company’s price to free cash flow for trailing twelve months was recorded as 0.
Historical Performances to Consider:
The Stock’s performances for Monthly, weekly, half-yearly, quarterly & year-to-date are mentioned below:
On a Monthly basis the stock was 22.55%. On a weekly basis, the stock remained -5.30%. The half-yearly performance for the stock has 132.39%, while the quarterly performance was 69.61%. Looking further out we can see that the stock has moved 45.52% over the year to date. Other technical indicators are worth considering in assessing the prospects for EQT. RSI for instance was stand at 59.38.
9 Meters Biopharma, Inc., a clinical-stage biotechnology company, focuses on patients with rare disorders and unmet needs. The company’s pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease. It is developing NM-002, a long-acting injectable GLP-1 agonist that is in a Phase 2 clinical trial for SBS; and Larazotide, a Phase 3-stage therapeutic in development for celiac disease. The company also develops NM-003, a proprietary long-acting GLP-2 agonist; and NM-004, a double-cleaved mesalamine with an immunomodulator for developing rare and/or orphan indications. 9 Meters Biopharma, Inc. is based in Raleigh, North Carolina.